BTCC
/
BTCC Square
/
Global Cryptocurrency
/
Novo Nordisk to Acquire Akero Therapeutics in $5.2 Billion Deal
Novo Nordisk to Acquire Akero Therapeutics in $5.2 Billion Deal
15
2
BTCCSquare news:
Akero Therapeutics (AKRO) surged 16% Thursday after Novo Nordisk announced a definitive agreement to acquire the biotech firm in an all-cash deal worth up to $5.2 billion. The offer includes $54 per share plus a contingent value right (CVR) tied to FDA approval of Akero's liver disease drug efruxifermin by 2031.
The acquisition, unanimously approved by Akero's board, highlights continued consolidation in the biopharma sector as major players seek to bolster pipelines. Novo Nordisk, Maker of weight-loss drug Wegovy, gains a promising MASH treatment candidate while Akero shareholders receive a significant premium over recent trading levels.
By:
